Celldex Therapeutics Stock Investor Sentiment
| CLDX Stock | USD 22.67 0.23 1.00% |
Slightly above 55% of Celldex Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Celldex Therapeutics suggests that many traders are impartial. Celldex Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Celldex Therapeutics' earnings reports, geopolitical events, and overall market trends.
Comfort Level 45
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Celldex Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Celldex Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Celldex Historical Sentiment
Although Celldex Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Celldex, such as negative comments on social media and news outlets, may cause fear in the market and push Celldex Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Celldex.
Celldex Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Celldex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Celldex Therapeutics Historical Investor Sentiment
Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Celldex Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Celldex Therapeutics' Stock prices. Below is the latest headlines and news related to Celldex Therapeutics Stock. Current markets are strongly bullish. About 71% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Celldex Therapeutics that are available to investors today. This information is accessible both publicly - through Celldex Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Celldex-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Celldex Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Celldex Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Celldex Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Celldex Therapeutics alpha.
Celldex Largest EPS Surprises
Earnings surprises can significantly impact Celldex Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-05 | 2021-06-30 | -0.4 | -0.34 | 0.06 | 15 | ||
2021-05-06 | 2021-03-31 | -0.345 | -0.42 | -0.075 | 21 | ||
2022-08-08 | 2022-06-30 | -0.51 | -0.59 | -0.08 | 15 | ||
2020-08-06 | 2020-06-30 | -0.58 | -0.5 | 0.08 | 13 | ||
2024-02-26 | 2023-12-31 | -0.74 | -0.83 | -0.09 | 12 | ||
2021-11-09 | 2021-09-30 | -0.36 | -0.45 | -0.09 | 25 |
There is far too much social signal, news, headlines, and media speculation about Celldex Therapeutics that are available to investors today. This information is accessible both publicly - through Celldex Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Celldex-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Celldex Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Celldex Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Celldex Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Celldex Therapeutics alpha.
Celldex Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Celldex price target lowered by 8 at H.C. Wainwright, heres why CLDX | 08/20/2025 |
2 | Celldex Therapeutics, Inc. Receives 46.67 Consensus Target Price from Brokerages | 09/09/2025 |
3 | Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16b-3 | 09/18/2025 |
4 | Acquisition by Richard Wright of 28469 shares of Celldex Therapeutics at 28.0 subject to Rule 16b-3 | 09/26/2025 |
5 | Celldex Therapeutics Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor Focus | 10/15/2025 |
6 | Barclays Initiates Coverage of Celldex Therapeutics With an Underweight Rating | 10/21/2025 |
7 | Celldex Therapeutics Evaluating Valuation After Barclays Underweight Rating and Industry Concerns | 10/23/2025 |
8 | Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition | 10/30/2025 |
9 | Published on 2025-11-05 005507 - newser.com | 11/04/2025 |
10 | Celldex announces additional data on barzolvolimab CLDX | 11/06/2025 |
11 | Celldex to Present at Upcoming Investor Conferences | 11/07/2025 |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.